CLChunyu Li

Chunyu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chunyu Li has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Cao

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

    4 shared publications
  • Guohui Li

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    3 shared publications
  • Jing Xu

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

    3 shared publications
  • Jiahui Yang

    CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

    2 shared publications
  • Nuoxian Yu

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China

    2 shared publications
  • Xiaofei Fei

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

    2 shared publications

Latest Publications

  • Open Access

    Revealing the pathogenesis of autoimmune hepatitis and research progress in drug discovery from hepatic immune cells and intercellular communication signaling mechanisms

    by Jie Yang, Hongying Zhou, Xiao Ma, Xuelin Zhou, Shizhang Wei, Yanling Zhao, Chunyu Li

    Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease with an increasing incidence. The complex pathogenesis of AIH poses significant challenges for clinical treatment. In recent years, with the introduction of cutting-edge concepts such as “immune–metabolic interplay” and “intercellular communication networks,” along with novel detection methods and technologies, research on the pathogenesis of AIH has shifted from a single-molecular-mechanism perspective to a systematic regulatory network analysis. This shift has not only provided more research evidence for a deeper understanding of the molecular biological mechanisms underlying AIH but also offers a potential reference for the development of targeted therapeutic drugs for AIH based on novel targets. Therefore, this review starts with aberrant activation signals from key immune cells—including dendritic cells (DCs), macrophages (Mφ), and T/B cells—and integrates the intercellular signaling communication mechanisms between hepatocytes, cholangiocytes, and immune cells to systematically summarize the key molecular biological mechanisms and targets identified in recent years, providing a reference for future elucidation of the critical mechanisms of AIH. On this basis, the review further integrates the current application and research progress of clinically used AIH therapeutic drugs, as well as those at various stages of development, including potential therapeutic compounds. It discusses the limitations of current clinical drugs and evaluates the feasibility and future application potential of potential compounds for AIH treatment in preclinical and clinical studies, thereby offering comprehensive research evidence for the management of AIH.

  • Mechanism exploration of Salvia miltiorrhiza Bunge against trastuzumab induced cardiotoxicity via multi-omics

    by Nuoxian Yu, Bo Cao, Jiahui Yang, Jing Xu, Mingyu Zhang, Xiaofei Fei, Zhuo Man, Jiabo Wang, Chunyu Li, Guohui Li

  • Prevention and Treatment of Doxorubicin and Trastuzumab-Induced Cardiotoxicity with Compound Danshen Dripping Pill

    by Nuo-Xian Yu, Meng-Meng Lin, Jing Xu, Bo Cao, Jia-Hui Yang, Rui-Sheng Li, Guo-Hui Li, Chun-Yu Li

    Objective To elucidate the therapeutic effect and mechanism of Compound Danshen Dripping Pill (CDDP) on cardiotoxicity caused by doxorubicin (DOX) and trastuzumab (TRZ) Methods Eighteen Sprague-Dawley (SD) rats were randomly divided into the normal group (normal saline), the model group (DOX/TRZ), and CDDP administration group (DOX/TRZ+CDDP), by a random number table, with 6 rats in each group. Rats’ were administered either DOX or saline via tail vein injection 6 times over an 11-day period. One week later, they received either TRZ or saline via intraperitoneal injection 6 times over another 11-day period. All rats received CDDP or saline via oral gavage continuously for 36 days. Then, echocardiography was performed on the rats, and biochemical parameters of blood and heart samples were determined. Rats’ feces were taken for intestinal flora testing and plasma metabolites were analyzed using untargeted metabolomics. Results Echocardiographic assessment in rats demonstrated that DOX/TRZ induced cardiac dysfunction, whereas CDDP significantly ameliorated this impairment (PPPPClostridia_UCG-014 and Lactobacillus) with CDDP treatment. Conclusions CDDP can prevent and protect against DOX/TRZ-induced cardiac injury. It influences tryptophan metabolism by modulating Clostridia_UCG-014 abundance, inhibits indole-3-carboxylic acid levels, increases kynurenine levels, thereby exerting anti-cardiotoxic effects.

  • Open Access

    Protective Effect of Xihuang Pill on Immune Checkpoint Inhibitors-Related Myocarditis in a Mouse Model by Regulating the HIF-1 Signaling Pathway

    by Bo Cao, Huijuan Xie, Jing Xu, Nuoxian Yu, Zhuo Man, Wenwen Zhao, Guohui Li, Chunyu Li, Li Han

    Background: Immune checkpoint inhibitor (ICIs)-associated cardiotoxicity is a significant cause of immune-related adverse events and mortality in cancer immunotherapy, lacking effective preventative or therapeutic strategies. Xihuang Pill (XHW), a traditional Chinese medicine with established anti-inflammatory properties and clinical use in cancer treatment and adverse event mitigation, merits investigation for its efficacy against ICIs-induced cardiac toxicity. Purpose: To investigate XHW’s therapeutic effects on Immune checkpoint inhibitors (ICIs)-associated cardiotoxicity and its underlying mechanisms. Methods: This study utilized mass spectrometry technology to identify the chemical components in XHW. The experimental model for ICIs-associated myocarditis was generated in BALB/c mice by immunizing them with murine cardiac troponin I (cTnI) peptide and administering anti-programmed death 1 (PD-1) antibodies to mice. Mice received varying XHW dosages (0.39, 0.78, and 1.56 mg/kg). Myocardial contractility and plasma cardiac injury markers (CK, CK-MB) were assessed. Metabolomics and transcriptomics identified key signaling pathways modulated by XHW, validated via real-time quantitative PCR (QT-PCR). In addition, a correlation analysis was conducted between key genes and differential metabolites. Results: Mass spectrometry identified 171 components in XHW. Pharmacological studies demonstrated that XHW improved cardiac contractility, reduced plasma cardiac injury biomarkers, and attenuated myocardial injury in the myocarditis model. Integrated metabolomic and transcriptomic analyses revealed that XHW primarily modulates the HIF-1 signaling pathway, significantly upregulating HIF-1 mRNA expression and downregulating the mRNA expression of Nppa, Angpt1, Angpt2, and Trf. Correlation analysis identified significant associations between 16 metabolites, including 13-tetradecynoic acid, 1-pentadecanoylglycerol, and arginyl-glycyl-aspartic acid, and these genes. Conclusion: These findings suggest that XHW may alleviate ICIs-associated myocarditis via HIF-1 signaling pathway, offering a promising therapeutic approach for ICIs-related cardiotoxicity.


  • Open Access

    Epimedii Folium flavonoids: A double-edged sword effect on the liver, a dual exploration of efficacy and toxicity

    by Meijun Yue, Yanlu Liu, Xiaoan Feng, Bo Cao, Xiaofei Fei, Guohui Li, Chunyu Li